Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Virology. 2021 Aug 5;562:197–208. doi: 10.1016/j.virol.2021.08.001

Figure 5:

Figure 5:

Serological responses to the combined administration of NA1 + NA2 VLPs. Groups of BALB/c mice were vaccinated IM in a prime-boost regimen 28 days apart with 10 µg NA1 + NA2 VLPs (5 µg NA1 VLPs + 5 µg NA2 VLPs), 10 µg NA1 VLPs, 10 µg NA2 VLPs or mock vaccinated with PBS. (A) Total serum anti NA2 IgG responses measured by ELISA at 14 days post-prime vaccination. (B) Total serum anti NA2 IgG responses measured by ELISA at 14 days post-boost vaccination. (C) Neuraminidase inhibition (NAI) titers against NA2 VLPs measured 14 days post-boost vaccination. (D) Total serum anti NA1 IgG responses measured by ELISA at 14 days post-prime vaccination. (E) Total serum anti NA1 IgG responses measured by ELISA at 14 days post-boost vaccination. (F) NAI titers against NA1 VLPs measured 14 days post-boost vaccination. N=5 mice per group. Error bars represent SEM. *= p<0.05; ***=p<0.001; ****=p<0.0001.